Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}
ABM
GRAFT DYSFUNCTION, GRAFT LOSS
A metabolic assessment of the liver biopsies will be performed. Using pre-defined criteria (lactate > 8.4 and/or phosphocholine > 0.646), the level of MELG (metabolically extended liver grafts) both before and after machine perfusion will be compared within the experimental group. The level of MELG in both groups (experimental and control) will also be correlated with the risk of graft dysfunction or graft loss at 1 year.In the control group, a biopsy of the liver graft will be taken at the beginning of the back-table preparation. Another biopsy will be taken after liver graft reperfusion in the recipient (routine practice).In the experimental group, a biopsy of the liver graft will be taken at the beginning of the back-table preparation. Another biopsy will be taken at the end of the HOPE perfusion, and a third biopsy will be taken after liver graft reperfusion in the recipient (routine practice).Immediately after collection (maximum 5 min after collection), the biopsy will be placed in 2-ml microvials to be either frozen in liquid nitrogen or put in allprotect®. They will then be stored at − 80 °C in each center.Biopsies, realized at the beginning of the black-table for both groups and at the end of the HOPE perfusion for the experimental group, will be centralized at the end of the study at I-Cube laboratory (UMR 7357—Pr IJ Namer at l) in Strasbourg, France, for analysis. Approximately 30 metabolites of interest will be analyzed by spectrometry (Brucker Avance III 500 spectrometer). A histological study of the samples analyzed by spectroscopy will also be performed. The samples will be destroyed at the end of the analysis.Since those biopsies will be performed on a liver graft from a deceased donor, an authorization from the Agence de la Biomédecine (ABM) was required and has been obtained.